secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001213900-21-064319
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals appoints Cary Claiborne as COO effective Dec 6, 2021
--------------------------------------------------------------------------

- Cary Claiborne appointed COO; continues to serve on Board of Directors.
- Employment agreement: $304,000 base salary, 25% target bonus, three-year term.
- Awarded option to purchase 130,000 shares at $2.77, vesting monthly over 36 months.
- Joseph Truluck resigns as COO but remains CFO of the company.
- Press release issued December 8, 2021 announcing the appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390021064319/0001213900-21-064319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390021064319/ea151938-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-064319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer